Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03491384 · ClinicalTrials.gov registry record

Anxiety, Inflammation, Stress, and Cannabinoids

A clinical trial, sponsored by University of Colorado, Boulder.

Completed
Registry status
361
Enrollment target

NCT03491384 is a clinical trial that has completed, run by University of Colorado, Boulder. The registered enrollment target is 361 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03491384 has completed, sponsored by University of Colorado, Boulder.

COMPLETED
Registry status
361 participants
Enrollment target

Study Summary

This study investigates whether the anxiolytic effects and anti-inflammatory properties of cannabis vary as a function of the ratio of CBD to THC, with the goal that these effects may shed light on the mixed data linking cannabis use and anxiety. Individuals with mild to moderate anxiety who elect to use cannabis (smoked flower or edible) will complete four weeks of observation. Participants complete cognitive tasks, a substance use history, health questionnaires concerning sleep and physical activity, and a blood draw at four different time points (Baseline, after 2 weeks of cannabis use, and immediately before and after self-administration after 4 weeks of use) with the use of a mobile pharmacology laboratory, which goes to a convenient location for each participant to self-administer their cannabis. Participants are then followed for five months to self-report on cannabis use, anxiety, subjective cognitive functioning, sleep quality, and other mental health symptoms.

Interventions

  • DRUG Cannabis (smoked flower, ingested edible)

Trial Details

FieldValue
Enrollment Target 361 participants
Start Date 2018-04-01
Est. Completion 2023-05-17

Sponsor

University of Colorado, Boulder

69 total trials

What the Registry Record Tells You About NCT03491384

The ClinicalTrials.gov registry entry for NCT03491384 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Boulder, which has 69 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Cannabis (smoked flower, ingested edible) is the first listed.

NCT03491384 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03491384 about?

NCT03491384 is a clinical study titled "Anxiety, Inflammation, Stress, and Cannabinoids". This study investigates whether the anxiolytic effects and anti-inflammatory properties of cannabis vary as a function of the ratio of CBD to THC, with the goal that these effects may shed light on the mixed data linking cannabis use and anxiety. Individuals with mild to moderate anxiety who elect t...

What is the current status of trial NCT03491384?

This trial is currently completed. The enrollment target is 361 participants. The study started on 2018-04-01. Estimated completion is 2023-05-17.

What interventions are being tested in trial NCT03491384?

The interventions under investigation include: Cannabis (smoked flower, ingested edible) (DRUG).

Who is sponsoring clinical trial NCT03491384?

This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.